Brian Higgins
Overview
Explore the profile of Brian Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
3341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Uy G, Assouline S, Young A, Blotner S, Higgins B, Chen L, et al.
Invest New Drugs
. 2020 Feb;
38(5):1430-1441.
PMID: 32020437
In acute myeloid leukemia (AML), TP53 mutations and dysregulation of wild-type p53 is common and supports an MDM2 antagonist as a therapy. RO6839921 is an inactive pegylated prodrug of the...
12.
Abdul Razak A, Miller Jr W, Uy G, Blotner S, Young A, Higgins B, et al.
Invest New Drugs
. 2019 Nov;
38(4):1156-1165.
PMID: 31734832
Purpose MDM2 is a negative regulator of the tumor suppressor p53. RO6839921 is an inactive pegylated prodrug of idasanutlin, an MDM2 antagonist, developed for intravenous administration. On cleavage by plasma...
13.
14.
Mai W, Gosa L, Daniels V, Ta L, Tsang J, Higgins B, et al.
Nat Med
. 2017 Oct;
23(11):1342-1351.
PMID: 29035366
Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer. Here we show that although acute inhibition of EGFR-driven glucose metabolism induces only minimal...
15.
Vilgelm A, Cobb P, Malikayil K, Flaherty D, Johnson C, Raman D, et al.
EBioMedicine
. 2017 Oct;
24:43-55.
PMID: 29030058
Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage...
16.
Cunefare D, Cooper R, Higgins B, Katz D, Dubra A, Carroll J, et al.
Biomed Opt Express
. 2016 May;
7(5):2036-50.
PMID: 27231641
Quantitative analysis of the cone photoreceptor mosaic in the living retina is potentially useful for early diagnosis and prognosis of many ocular diseases. Non-confocal split detector based adaptive optics scanning...
17.
Martin P, Shiau C, Pasic M, Tsao M, Kamel-Reid S, Lin S, et al.
Br J Cancer
. 2016 Feb;
114(6):616-22.
PMID: 26889973
Background: We examined clinical outcomes in a population-based cohort of EGFR mutant advanced NSCLC patients, exploring the potential role of factors including tumour EGFR mutation fraction and cellularity in predicting...
18.
Levine M, Julian J, Bedard P, Eisen A, Trudeau M, Higgins B, et al.
J Clin Oncol
. 2015 Nov;
34(10):1065-71.
PMID: 26598746
Purpose: To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort. Patients And Methods: Patients with axillary node-negative or nodal micrometastases, estrogen receptor-positive, and human epidermal growth...
19.
Leung M, Florendo J, Kano J, Marr-Del Monte T, Higgins B, Myers R, et al.
Support Care Cancer
. 2014 Nov;
23(6):1669-77.
PMID: 25421443
Purpose: The short half-life of filgrastim allows for modification in the dose or duration of prophylaxis to limit inconvenience, adverse effects, and cost. The objectives of this study were to...
20.
Zhang Z, Ding Q, Liu J, Zhang J, Jiang N, Chu X, et al.
Bioorg Med Chem
. 2014 Jul;
22(15):4001-9.
PMID: 24997575
The field of small-molecule inhibitors of protein-protein interactions is rapidly advancing and the specific area of inhibitors of the p53/MDM2 interaction is a prime example. Several groups have published on...